Bigfoot Biomedical announced today that it secured $57 million in financing as it works toward commercializing its diabetes management program.
Madryn Asset Management provided the financing for Bigfoot, which is developing the Bigfoot Unity diabetes management program designed to simplify and connect aspects of insulin management to enable personalized, proactive and remote patient care, according to a news release. The Bigfoot Unity program features smar tpen caps that provide insulin dose decision support, enabling patients to follow doctors’ orders in a simple way.
Get the full story at our sister site, Drug Delivery Business News.